Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

NCT04637594 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Locally Advanced Urethral Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Nivolumab
DRUG: Atezolizumab
DRUG: Durvalumab
DRUG: Avelumab

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]